ALXO(ALXO)
ALXO
ANALYST COVERAGE7 analysts
BUY
▲ +101.0%upside to target
Key MetricsTTM
Market Cap$107.91M
Revenue TTM—
Net Income TTM—
Free Cash Flow—
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-124.1%
Return on Assets-49.8%
Debt / Equity—
Current Ratio7.21
EPS TTM—
PRICE
Prev Close
1.99
Open
1.99
Day Range1.97 – 2.02
1.97
2.02
52W Range0.40 – 2.66
0.40
2.66
70% of range
VOLUME & SIZE
Avg Volume
879.3K
FUNDAMENTALS
P/E Ratio
-1.3x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.73
High vol
TECHNICAL
RSI (14)
56
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19
ALXO News
About
ALX Oncology Holdings Inc. operates as a clinical stage immuno-oncology company. The Company focuses on helping patients fight cancer by developing therapies that bridge the innate and adaptive immune system. ALX Oncology Holdings serves patients in the State of California.
Industry
Research and Development in Biotechnology
Website
Jeff E. KnightChief Development & Operating Officer
Lisa SauerSenior Vice President of Regulatory Affairs & Quality Assurance
Shelly WongSenior Vice President of Finance & Chief Accounting Officer
Shelly PintoSenior Vice President of Finance & Chief Accounting Officer
Athanasios TsiatisSenior Vice President of Clinical Development
Barbara J. KlenckeChief Medical Officer
Lin Yeong-LiangSenior Vice President of Drug Safety & Pharmacovigilance
Harish ShantharamChief Financial Officer
Jason W. LettmannChief Executive Officer & Director
Venita De AlmeidaVice President & Head of Research Program Development
Sue NaimSenior Vice President of Clinical Operations